As a form of cancer more closely correlated with diet and lifestyle factors than other cancers, colorectal cancer (CRC) is on the rise1, with Adenocarcinomas being the most common form of CRC. Existing cancer prevention and screening best practices can help in the early identification of CRC to provide patients more options and the best opportunity to get the treatment they need.
With a broad portfolio of tumor markers, highly sensitive CRC assays, and oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics.
References
